South Korean pharmaceutical firm Boryung Corp. invested $10 million in lunar technology provider Intuitive Machines, deepening its push into space-based healthcare research.
The Seoul-based company purchased 952,381 Class A common shares as part of Intuitive Machines’ $65 million rights offering, according to a statement Friday. The investment follows a strategic partnership formed in December to develop lunar infrastructure for life science research.
The deal marks Boryung’s latest step to establish a foothold in space medicine, following previous collaborations with the Houston-based company to create experimental platforms for the Artemis moon program.
Intuitive Machines has already demonstrated its lunar capabilities through its IM-1 mission, when its Nova-C lander Odysseus successfully touched down near the moon’s south pole aboard a SpaceX Falcon 9 rocket. The company provides various space-related services across four business units, including lunar access and orbital operations.
The rights offering helps strengthen Intuitive Machines’ position in the growing commercial space sector as NASA and private companies race to establish a sustained presence on the lunar surface. The company aims to support both robotic and human exploration missions targeting the Moon and Mars.
